Invitrocue Invitrocue is a life sciences company that specializes in developing 3D cell-based models derived from liver and tumour tissues. | ![]() Epsilogen Epsilogen (formerly IGEM Therapeutics) is an immuno-oncology company specializing in the development of IgE antibody drugs to fight cancer.
| ![]() Artiva Biotherapeutics Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors. | ![]() Viracta Therapeutics Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases. | ![]() MedChemExpress MedChemExpress (MCE) is a company offering biochemical and life science research tools. | |
Founding Date | Founding Date 2012 | Founding Date 2017 | Founding Date 2019 | Founding Date 2016 | Founding Date 2009 |
Type | Type Public | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Singapore, SG HQ Sydney, AU Su Zhou Shi, CN München, DE Madrid, ES | Locations Reading, GB HQ London, GB | Locations San Diego, US HQ | Locations Encinitas, US HQ | Locations South Brunswick Township, US HQ |
Employees | Employees N/A | Employees 28 | Employees 81 | Employees 323% increase | Employees 1012% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 263.8 m | Valuation ($) 8.7 m | Valuation ($) N/A |
Financial | |||||
Net income | Net income ($6.7m) (FY, 2019) | Net income N/A | Net income ($83.9m) (FY, 2025) | Net income ($51.1m) (FY, 2023) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 78m | Total funding raised $ 18.4m | Total funding raised N/A |

Epsilogen (formerly IGEM Therapeutics) is an immuno-oncology company specializing in the development of IgE antibody drugs to fight cancer.
View company
Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors.
View company
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
View company
MedChemExpress (MCE) is a company offering biochemical and life science research tools.
View company